JPH11504801A - パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 - Google Patents

パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Info

Publication number
JPH11504801A
JPH11504801A JP8512335A JP51233596A JPH11504801A JP H11504801 A JPH11504801 A JP H11504801A JP 8512335 A JP8512335 A JP 8512335A JP 51233596 A JP51233596 A JP 51233596A JP H11504801 A JPH11504801 A JP H11504801A
Authority
JP
Japan
Prior art keywords
protein
virus
proteins
papillomavirus
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP8512335A
Other languages
English (en)
Japanese (ja)
Inventor
ラッツ ギッスマン
ジアン ゾウ
マーティン ミュラー
ジャネット ペインスティル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25940851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH11504801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19944435907 external-priority patent/DE4435907C2/de
Priority claimed from DE1995126752 external-priority patent/DE19526752C2/de
Application filed by Individual filed Critical Individual
Publication of JPH11504801A publication Critical patent/JPH11504801A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP8512335A 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Withdrawn JPH11504801A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19944435907 DE4435907C2 (de) 1994-10-07 1994-10-07 Papillomavirusähnliche Partikel und deren Anwendung
DE1995126752 DE19526752C2 (de) 1995-07-21 1995-07-21 Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
DE4435907.1 1995-07-21
DE19526752.4 1995-07-21
PCT/EP1995/003974 WO1996011272A2 (de) 1994-10-07 1995-10-09 Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005130613A Division JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Publications (1)

Publication Number Publication Date
JPH11504801A true JPH11504801A (ja) 1999-05-11

Family

ID=25940851

Family Applications (6)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Country Status (13)

Country Link
US (6) US6066324A (OSRAM)
EP (2) EP0809700B1 (OSRAM)
JP (6) JPH11504801A (OSRAM)
AT (1) ATE325875T1 (OSRAM)
AU (2) AU4270196A (OSRAM)
CA (1) CA2202090C (OSRAM)
DE (3) DE122007000092I1 (OSRAM)
DK (1) DK0809700T3 (OSRAM)
ES (1) ES2264563T3 (OSRAM)
LU (2) LU91390I2 (OSRAM)
NL (2) NL300324I1 (OSRAM)
PT (1) PT809700E (OSRAM)
WO (1) WO1996011272A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507797A (ja) * 2002-05-17 2006-03-09 ユニバーシティ・オブ・ケープ・タウン Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
CA2202090C (en) * 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
DE69734829D1 (de) 1996-07-17 2006-01-12 Us Health Infektiöse pseudovirale papillomavirus partikel
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
JP2001507352A (ja) * 1996-12-20 2001-06-05 メルク エンド カンパニー インコーポレーテッド 組換えパピローマウイルスワクチンの組成物
AU755679B2 (en) * 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AU2003200653B2 (en) * 1997-10-06 2007-01-18 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ES2275350T3 (es) * 1998-08-14 2007-06-01 MERCK & CO., INC. Sistema de administracion de proteinas usando particulas de tipo virus de papilomavirus humano.
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20040146531A1 (en) * 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
WO2008153541A1 (en) 2006-09-26 2008-12-18 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
CL2008000611A1 (es) 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
CN101293918B (zh) 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
BRPI0810951B8 (pt) * 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US8795676B2 (en) * 2007-11-23 2014-08-05 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma virus
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
CN102822672B (zh) 2010-01-08 2015-12-09 安科健康公司 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SG10201605265TA (en) * 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
AU2012272788B2 (en) 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
PT2744895E (pt) 2011-09-08 2016-02-08 Uniqure Ip Bv Remoção de vírus contaminantes de preparações de aav
EP3563834A1 (en) 2012-02-07 2019-11-06 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA3023968A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
AU2017273650B2 (en) 2016-06-01 2022-08-18 Access To Advanced Health Institute Nanoalum particles containing a sizing agent
ES3003260T3 (en) 2017-06-15 2025-03-10 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
KR102755593B1 (ko) 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
WO2021013063A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
CN114127097B (zh) * 2019-07-19 2024-09-17 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
MX2022000778A (es) * 2019-07-19 2022-02-14 Sinocelltech Ltd Proteina quimerica l1 del virus de papiloma humano.
WO2021013071A1 (zh) 2019-07-19 2021-01-28 神州细胞工程有限公司 人乳头瘤病毒多价免疫原性组合物
EP4103227A1 (en) 2020-02-14 2022-12-21 Merck Sharp & Dohme LLC Hpv vaccine
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
KR20240046247A (ko) 2021-08-19 2024-04-08 머크 샤프 앤드 돔 엘엘씨 열안정성 지질 나노입자 및 그의 사용 방법
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ES2279020T3 (es) * 1991-07-19 2007-08-16 The University Of Queensland Vacuna contra el papilomavirus humano.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
JPH07505412A (ja) * 1992-04-14 1995-06-15 ブリティッシュ　バイオテック　ファーマシューティカルズリミテッド Ｃｔｌ応答の誘導
EP0647140B1 (en) 1992-06-25 2007-12-12 Georgetown University Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DE122007000014I1 (de) * 1993-03-09 2007-05-24 Univ Rochester Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
CA2202090C (en) * 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
CA2211995A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507797A (ja) * 2002-05-17 2006-03-09 ユニバーシティ・オブ・ケープ・タウン Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法
JP2022519992A (ja) * 2018-12-28 2022-03-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド

Also Published As

Publication number Publication date
US6361778B1 (en) 2002-03-26
JP2012010713A (ja) 2012-01-19
CA2202090C (en) 2012-04-17
EP0809700A1 (de) 1997-12-03
DE122007000092I1 (de) 2008-03-27
EP1728800A1 (de) 2006-12-06
DE122007000093I1 (de) 2008-03-27
ATE325875T1 (de) 2006-06-15
JP5794747B2 (ja) 2015-10-14
US6599508B1 (en) 2003-07-29
JP2005270111A (ja) 2005-10-06
WO1996011272A3 (de) 1996-09-26
ES2264563T3 (es) 2007-01-01
PT809700E (pt) 2006-09-29
JP2013213034A (ja) 2013-10-17
JP2009102327A (ja) 2009-05-14
AU1010600A (en) 2000-03-16
CA2202090A1 (en) 1996-04-18
AU760615B2 (en) 2003-05-22
DE59511047D1 (de) 2006-06-14
JP2015037430A (ja) 2015-02-26
NL300324I1 (nl) 2008-03-03
NL300323I2 (nl) 2010-03-01
US20040202679A1 (en) 2004-10-14
DK0809700T3 (da) 2006-09-18
US7416732B2 (en) 2008-08-26
LU91401I2 (fr) 2008-02-14
US6066324A (en) 2000-05-23
NL300323I1 (nl) 2008-03-03
US20060153864A1 (en) 2006-07-13
US20110015376A1 (en) 2011-01-20
LU91390I2 (fr) 2008-02-14
AU4270196A (en) 1996-05-02
WO1996011272A2 (de) 1996-04-18
EP0809700B1 (de) 2006-05-10

Similar Documents

Publication Publication Date Title
JPH11504801A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP5296665B2 (ja) ヒトパピローマウイルスカプソメアワクチン製剤の製造方法
JP2003024058A (ja) パピロマウイルス偽ウイルス及びその調製方法
US6991795B1 (en) Protein delivery system using human papillomavirus virus-like particles
CA2339324C (en) Protein delivery system using human papillomavirus virus-like particles
US7182947B2 (en) Papillomavirus truncated L1 protein and fusion protein constructs
Kelsall et al. Expression of the major capsid protein of human papillomavirus type 16 in Escherichia coli
AU2003235191B2 (en) Papilloma virus-like particles, fusion proteins as well as processes for their production
AU2006252125B2 (en) Papiloma virus-like particles, fusion proteins as well as processes for their production
US7494658B2 (en) Papilloma virus truncated L1 protein and fusion protein constructs
JP2002507625A (ja) パピローマウイルス特異的タンパク質を含む配合物、その調製および使用
HK1094340A (en) Papilloma virus capsomere vaccine formulations and methods of use

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20051124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20060105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081029